IMB-XMA0038

CAS No. 921812-26-2

IMB-XMA0038( —— )

Catalog No. M36379 CAS No. 921812-26-2

IMB-XMA0038 is a novel inhibitor targeting Mycobacterium tuberculosis aspartate semialdehyde dehydrogenase with antimicrobial activity for use in tuberculosis research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    IMB-XMA0038
  • Note
    Research use only, not for human use.
  • Brief Description
    IMB-XMA0038 is a novel inhibitor targeting Mycobacterium tuberculosis aspartate semialdehyde dehydrogenase with antimicrobial activity for use in tuberculosis research.
  • Description
    IMB-XMA0038 is a novel inhibitor targeting Mycobacterium tuberculosis aspartate semialdehyde dehydrogenase with antimicrobial activity for use in tuberculosis research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    Dehydrogenase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    921812-26-2
  • Formula Weight
    294.22
  • Molecular Formula
    C11H10N4O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=CC=C([N+]([O-])=O)O1)NC2=NN=C(C3OCCC3)O2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • DHODH-IN-16

    DHODH-IN-16 is an effective inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 0.396 nM for human).

  • MF-438

    MF-438 is an effective and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor (EC50: 2.3 nM for rSCD1). In a mouse model, MF-438 shows an ED50 between 1 and 3 mg/kg.

  • IDH1-IN-1

    Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).